IL17A and ankylosing spondylitis: From these findings, the combined blocking of TNF-α and IL-17A may represent a new option for controlling inflammatory bone disorders as in RA, psoriatic arthritis as well as in ankylosing spondylitis and inflammatory subsets of OA and even common osteoporosis.